key: cord-0926044-5n9j69d0
authors: Guenthart, Brandon A.; Krishnan, Aravind; Alassar, Aiman; Madhok, Jai; Kakol, Monika; Miller, Shari; Cole, Sheela Pai; Rao, Vidya K.; Acero, Natalia Martinez; Hill, Charles C.; Cheung, Cindy; Jackson, Ethan C.; Feinstein, Igor; Tsai, Albert H.; Mooney, Joshua J.; Pham, Thomas; Elliott, Irmina A.; Liou, Douglas Z.; La Francesca, Saverio; Shudo, Yasuhiro; Hiesinger, William; MacArthur, John W.; Brar, Nivaz; Berry, Gerald J.; McCarra, Matthew B.; Desai, Tushar J.; Dhillon, Gundeep S.; Woo, Y. Joseph
title: First lung and kidney multi-organ transplant following COVID-19 Infection
date: 2021-05-02
journal: J Heart Lung Transplant
DOI: 10.1016/j.healun.2021.02.015
sha: 028998fddccd78acddf80ef741b4e27f8f3aa178
doc_id: 926044
cord_uid: 5n9j69d0

As the world responds to the global crisis of the COVID-19 pandemic an increasing number of patients are experiencing increased morbidity as a result of multi-organ involvement. Of these, a small proportion will progress to end-stage lung disease, become dialysis dependent, or both. Herein, we describe the first reported case of a successful combined lung and kidney transplantation in a patient with COVID-19. Lung transplantation, isolated or combined with other organs, is feasible and should be considered for select patients impacted by this deadly disease.

Broad extra-pulmonary manifestations of COVID-19 are being recognized 1 . Notably, SARS-COV-2 has selective kidney tropism, leading to acute kidney injury, found in over 40% of hospitalized patients with COVID-19 in the US [2] [3] [4] . Patients who subsequently require dialysis have a poor prognosis with a mortality rate over 75%; among patients who survive to discharge, over 30% will not recover their kidney function and require dialysis 3 .

Patients who recover from severe COVID-19 may be left with end-stage multi-organ dysfunction 5 .

There are no reports of kidney or multi-organ transplantation for the treatment of end-stage pulmonary and renal failure due to COVID-19. Herein, we present the first combined lung and kidney transplantation for the successful treatment of end stage pulmonary and renal failure due to COVID-19.

A 54-year-old man with no past medical history presented to the emergency department with 5 days of non-productive cough, pleuritic chest pain, and high-grade fevers. He was diagnosed with COVID-19. Within 24 hours of presentation, he required mechanical ventilation and was managed with lung protective ventilation, inhaled pulmonary vasodilators, neuromuscular blockade, and prone positioning. Subsequently, he received remdesivir, methylprednisolone, tocilizumab, and convalescent plasma. On hospital day 18, he required initiation of venovenous-extracorporeal membrane oxygenation (VV-ECMO). By hospital day 21 he developed acute kidney injury requiring continuous renal replacement therapy (CRRT).

Interval chest imaging revealed progressive and near complete bilateral airspace opacification superimposed on diffuse bronchiectasis (Figure 1) . Despite aggressive supportive care, his ARDS progressed to end-stage fibrotic lung disease along with the development of cor pulmonale.

He underwent extensive rehabilitation, and at the time of transplantation was neurologically intact and able to sit at the edge of bed for 20 minutes and stand with maximal assist.

The patient was taken to the operating room after suitable donor organs (lungs and kidney) were allocated from a single donor. With on-going ECMO support, the patient underwent median sternotomy, cardiopulmonary bypass (CPB) and donor lungs were implanted in standard fashion.

The patient was separated from CPB, without the need to re-initiate ECMO support (Supplemental Video 1). Following lung transplantation, the patient remained hemodynamically stable, and 5 hours later, was taken back to the operating room to undergo a deceased donor kidney transplant.

Post-operatively, the patient received standard triple immunosuppressive therapy with tacrolimus, methylprednisolone, and mycophenolate mofetil. Upon discharge to a rehabilitation center, he was on room air with a Cr of 0.42 mg/dL. The patient is now over 90 days post-transplant and recovering well at home. For a complete description of the clinical course, surgical procedure, and pathologic findings please refer to Supplementary Information.

Our experience suggests that in appropriately selected candidates who have exhausted conventional therapeutic options, multi-organ transplantation is both safe and feasible. In the present case, given the patient's radiographic findings of irreversible fibrosis and lack of improvement in pulmonary function despite maximal medical therapy and the prolonged utilization of ECMO, transplantation was the only life-saving intervention available. Histopathologic assessment of the explanted lungs confirmed this clinical assessment (Figure 2-3) .

This patient was a suitable candidate for multi-organ transplantation given his relatively young age and lack of significant medical comorbidities prior to COVID-19. Determining transplant candidacy included consideration of standard risk assessment such as age, ability to participate in rehabilitation, and clinical and radiographic evidence of irreversible disease having allowed for sufficient time for recovery of organ function. In the setting of COVID-19, this case challenges previous recommendations which mandate single organ involvement for transplant candidacy. 6 Confirmation of negative SARS-COV-2 PCR to ensure recovery from COVID-19 is also a necessity when considering single or multi-organ transplantation. 7 At our institution, we perform combined lung and kidney transplantation in a staged approach. Due to the high acuity of combined end-stage pulmonary and renal dysfunction, this approach may be a suitable course for centers considering multi-organ transplantation for patients who have recovered from severe COVID-19 infection.

With the progression of the COVID-19 pandemic and the high incidence of acute kidney injury in the critically ill subset of infected patients, combined end-stage pulmonary and renal failure will become an increasingly common presentation. [2] [3] [4] Our successful use of combined lung and kidney transplantation should serve as cause for consideration for other centers in the treatment of multiorgan failure due to COVID-19. 

The authors have no conflicts of interest related to the subject matter.

The authors received no financial support for the research, authorship, and/or publication of this article. 

Organ-specific manifestations of COVID-19 infection

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine

AKI in Hospitalized Patients with COVID-19

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney international

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

When to consider lung transplantation for COVID-19. The Lancet Respiratory Medicine

Factors Associated With Surgical Mortality and Complications Among Patients With and Without Coronavirus Disease 2019 (COVID-19) in Italy